Skip to main content
. 2015 Jan 10;6(6):4180–4189. doi: 10.18632/oncotarget.2907

Figure 2. 5-Year Kaplan-Meier survival analyses for emerged stage-specific biomarkers in expanded population of melanoma patients.

Figure 2

(a) Strong BRAF expression significantly correlates with worse 5-year survival in AJCC Stage I patients (73 patients, P = 0.010, Log-rank test). (b) Strong MMP2 expression significantly correlates with worse 5-year survival in AJCC Stage II patients (123 patients, P < 0.001, Log-rank test). (c) Strong cytoplasm p27 expression significantly correlates with worse 5-year survival in AJCC Stage III patients (95 patients, P = 0.018, Log-rank test). (d) Strong cytoplasm p27 expression significantly correlates with worse 5-year survival in AJCC Stage IV patients (49 patients, P = 0.046, Log-rank test).